Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts
-
Bang, Yung-Jue (Seoul National University College of Medicine)
;
Su, Wu-Chou (National Cheng Kung University Hospital) ;
Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ;
Nam, Do-Hyun (Samsung Medical Center) ;
Lim, Wan Teck (National Cancer Centre) ;
Bauer, Todd M. (PLLC) ;
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Poon, Ronnie Tung Ping (Queen Mary Hospital) ;
Hong, David (University of Texas/MD Anderson Cancer Center) ;
Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ;
Akimov, Mikhail (Novartis Pharma AG) ;
Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ;
Zhao, Sylvia (China Novartis Institutes for Biomedical Research) ;
Giovannini, Monica (Novartis Pharmaceuticals Corporation) ;
Ma, Brigette (The Chinese University of Hong Kong)
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
